➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Express Scripts
Baxter
Mallinckrodt
Moodys
Medtronic

Last Updated: June 5, 2020

DrugPatentWatch Database Preview

Cetuximab - Biologic Drug Details


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for cetuximab

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Yanhong DengPhase 3
Medical University of ViennaPhase 2
Yuhong LiPhase 2

See all cetuximab clinical trials

Recent Litigation for cetuximab

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
Ravgen, Inc. v. Natera, Inc.2020-06-01
Ravgen, Inc. v. PerkinElmer Inc.2020-06-01
CELGENE CORPORATION v. DR. REDDY'S LABORATORIES, LTD.2019-07-12

See all cetuximab litigation

PTAB Litigation
PetitionerDate
GEMoaB Monoclonals GmbH2019-12-20
2018-09-14
2018-01-08

See all cetuximab litigation

Pharmacology for cetuximab
Mechanism of ActionHER1 Antagonists

Company Disclosures: US Patents for cetuximab

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Imclone ERBITUX cetuximab VIAL; INTRAVENOUS 125084 001 2004-06-18   Start Trial Rhone-Poulenc Rorer International (Holdings), Inc. (Greenville, DE) 2018-04-17 RX Orphan company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for cetuximab

These patents were identified by searching patent claims

International Patents for cetuximab

Supplementary Protection Certificates for cetuximab

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0753 Netherlands   Start Trial PRODUCT NAME: TRASTUZUMAB EN RECOMBINANT HUMAAN HYALURONIDASE; REGISTRATION NO/DATE: EU/1/00/145/002 20130826
2016022 Lithuania   Start Trial PRODUCT NAME: RITUKSIMABAS; REGISTRATION NO/DATE: EU/1/98/067/001-002 20140321
2016 00031 Denmark   Start Trial PRODUCT NAME: RITUXIMAB AND RECOMBINANT HUMAN HYALURONIDASE; REG. NO/DATE: EU/1/98/067 20140326
2015 Austria   Start Trial PRODUCT NAME: POMALIDOMID UND SEINE PHARMAZEUTISCH AKZEPTABLEN SALZE, SOLVATE, HYDRATE ODER STEREOISOMERE; REGISTRATION NO/DATE: EU/1/13/850 20130805
1021 Netherlands   Start Trial PRODUCT NAME: TALAZOPARIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/19/1377 20190624
140 Estonia   Start Trial
2015 00006 Denmark   Start Trial PRODUCT NAME: POMALIDOMID OG FARMACEUTISK ACCEPTABLE SALTE, SOLVATER, HYDRATER ELLER STEREOISOMERER HERAF; REG. NO/DATE: EU/1/13/850 20130805
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Medtronic
Express Scripts
McKinsey
Dow
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.